18 December 2015 - The EMA has recommended granting a conditional marketing authorisation for Tagrisso (osimertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer with a specific mutation (T790M) of the epidermal growth factor receptor.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002448.jsp&mid=WC0b01ac058004d5c1